Although trastuzumab significantly improves DFS(disease-free survival) in patients with HER2-positive breast cancer (Slamon et al., 2011), approximately one in four patients with the early-stage disease will relapse within the first decade after trastuzumab treatment. This evidence concerns the gene ERBB2 and breast cancer.